$12M patient may have contributed to insurer’s exit from Iowa

A single patient’s astronomical medical bills may have been a factor in Iowa’s largest insurer, Wellmark Blue Cross and Blue Shield, exiting the state’s individual market for 2018. Talking about that patient, however, may have put a company executive in violation of HIPAA.

When Wellmark announced its departure from the individual market in April, it blamed a “small subset” putting its larger customer base in jeopardy as it racked up $90 million in losses in three years on the Affordable Care Act exchange.

That small subset contained a particularly expensive patient: a teenage boy with hemophilia. Wellmark Executive Vice President Laura Jackson described that patient, without giving his name or hometown, to a Des Moines Rotary Club meeting, according to the Des Moines Register.

The disease can be managed with concentrated solutions of “factors,” proteins which help the blood’s ability to clot. Some severe cases require several shots per day of the expensive treatment, but the Hemophilia Foundation of America said the upper limit for care is usually $1 million per year, not per month.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.